By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr

We discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples...

By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher

In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than...

By Helen Stewart-Miller and Kate Tointon

In this article, we look at how commercial products and services are facilitating the automation of cell-based assays to advance drug discovery and...

By Dr Anne-Marie Zuurmond, et al.

New disease targets frequently emerge in literature, but the thorough target validation required to consider these targets for a drug discovery pro...

By Jon Newman-Smith

Developing and maintaining cell cultures in a stable and sterile environment is of paramount importance to protect samples and increase overall suc...

By Pierre-Louis Joffrin

Despite major investment in the field, few cell therapies have gained regulatory approval with limited commercial success.

By Sumit Jamuar, et al.

The publication of the first human genome sequence more than 15 years ago marked the start of a new era in medicine. In the years since then, resea...

By Mike Furness and John Wise

Bioinformatics has played a major role in gene sequencing diagnostics and has been an essential tool to investigate the genetic causes of disease. ...